AI Telephone

James Brown, a male born in 1957, has no known drug allergies. He has active diagnoses of type 2 diabetes mellitus, diabetic nephropathy, chronic kidney disease stage 3B, and hypertension. A recent laboratory observation shows an estimated Glomerular Filtration Rate (eGFR) of 38 mL/min/1.73m2.

To manage his conditions, Mr. Brown is currently prescribed the following medications:

• Metformin 500mg twice daily (noted as a reduced dose for chronic kidney disease)
• Losartan 50mg daily for renal protection
• Amlodipine 5mg daily for hypertension
• Calcitriol 0.25mcg daily for vitamin D deficiency

Additionally, there is an active service order for a basic metabolic panel to regularly monitor his renal function and electrolytes in relation to his stage 3B chronic kidney disease.

James Brown is a 66-year-old male with no known drug allergies (NKDA).

Active Conditions:

Mr. Brown carries a diagnosis of Type 2 diabetes mellitus complicated by diabetic nephropathy, which has progressed to Stage 3b chronic kidney disease (CKD), classified as severe. His most recent estimated glomerular filtration rate (eGFR) is 38 mL/min/1.73m², which is significantly below the normal threshold of ≥90 mL/min/1.73m². He also has active hypertension and vitamin D deficiency.

Current Medications:

1. Losartan 50 mg orally once daily — prescribed for renal protection in the setting of diabetic nephropathy and CKD.
2. Metformin 500 mg orally twice daily — for glycemic control of Type 2 diabetes. The dose has been reduced from the standard regimen due to his CKD Stage 3b (eGFR 38), with a note to monitor renal function regularly.
3. Amlodipine 5 mg orally once daily — for blood pressure control.
4. Calcitriol 0.25 mcg orally once daily — for treatment of vitamin D deficiency.

Pending Laboratory Orders:

1. Renal function panel — ordered for regular monitoring of renal function in the context of CKD Stage 3b management and to guide metformin dose adjustment.
2. Electrolytes panel — ordered for regular electrolyte monitoring due to CKD and concurrent losartan therapy, given the associated risk of hyperkalemia.

James Brown is a 67-year-old male patient with a complex medical history. He has been diagnosed with Stage 3b Chronic Kidney Disease (CKD), which was confirmed in January 2020 and is noted to have an eGFR of 38, secondary to diabetic nephropathy. Additionally, he has active Type 2 Diabetes and Hypertension. Mr. Brown's current medication regimen includes Losartan 50mg daily, Metformin 500mg twice daily (with a note indicating a reduced dose due to his CKD), Amlodipine 5mg daily, and Calcitriol 0.25mcg daily. He has active service requests for renal function monitoring and electrolyte monitoring, both of which are to be performed every three months. Notably, Mr. Brown has no known drug allergies.

James Brown (male, born 1959) has no known drug allergies (active, confirmed).

He carries multiple active, confirmed problem-list diagnoses, including chronic kidney disease (CKD) stage 3b (SNOMED 433146000; ICD-10 N18.32) with staging noted as “Stage 3b (eGFR 38)”. Supporting laboratory evidence includes a final estimated GFR (CKD-EPI) of 38 mL/min/1.73 m². The CKD is noted as secondary to diabetic nephropathy. Additional active conditions include diabetic nephropathy, type 2 diabetes mellitus, hypertension, and vitamin D deficiency.

Current active medication orders include:

• Losartan potassium 50 mg oral tablet: 50 mg by mouth once daily, indicated for renal protection, associated with CKD.
• Metformin hydrochloride 500 mg oral tablet: 500 mg by mouth twice daily (noted as a reduced dose for CKD), associated with type 2 diabetes and CKD.
• Amlodipine 5 mg oral tablet: 5 mg by mouth once daily for blood pressure, associated with hypertension.
• Calcitriol 0.25 mcg oral capsule: 0.25 mcg by mouth once daily for vitamin D deficiency, associated with vitamin D deficiency and CKD.

Two active laboratory service requests have been placed for ongoing monitoring due to CKD stage 3b:

• Renal function panel (serum/plasma) (LOINC 24362-6) for regular monitoring of renal function, with note indicating monitoring is required due to CKD stage 3b.
• Electrolytes panel (serum/plasma) (LOINC 24357-6) for regular monitoring of electrolytes, with note indicating monitoring is required due to CKD and antihypertensive therapy.

James Brown, a 66-year-old male, has a complex medical history including chronic kidney disease stage 3B, diabetic nephropathy, type 2 diabetes mellitus, hypertension, and vitamin D deficiency. His glomerular filtration rate is significantly reduced at 38 mL/min/1.73m². He is currently managed on a regimen of losartan potassium 50mg daily for renal protection, metformin hydrochloride 500mg twice daily with a reduced dose for his chronic kidney disease, amlodipine 5mg daily for hypertension, and calcitriol 0.25mcg daily for vitamin D deficiency. Regular monitoring of his renal function and electrolytes has been ordered through basic metabolic panels. Notably, the patient has no known drug allergies.

James Brown, a male born in 1959, has no known drug allergies. His active problem list is significant for type 2 diabetes mellitus complicated by diabetic nephropathy, stage 3b chronic kidney disease (CKD), essential hypertension, and vitamin D deficiency. A recent laboratory test on March 9, 2026, revealed a low estimated Glomerular Filtration Rate (eGFR) of 38 mL/min/1.73 m2, which is consistent with his CKD secondary to diabetic nephropathy.

To manage his conditions, Mr. Brown is currently prescribed several oral medications: losartan potassium 50 mg once daily (for his CKD), metformin hydrochloride 500 mg twice daily (a reduced dose for his CKD and diabetes), amlodipine 5 mg once daily (for hypertension), and calcitriol 0.25 mcg once daily (for vitamin D deficiency and CKD).

For ongoing management and regular monitoring of his stage 3b chronic kidney disease, active laboratory orders have been placed for a renal function panel and a basic metabolic panel. Both tests are scheduled to be drawn every 3 months to monitor his overall renal function and electrolytes.

James Brown is a 69-year-old male with a complex medical history involving multiple chronic conditions. He has a confirmed diagnosis of hypertension dating back to 2005, type 2 diabetes mellitus with onset in 2010, and stage 3B chronic kidney disease (CKD) of moderate severity, first identified in 2015. His most recent estimated glomerular filtration rate (eGFR), obtained on May 15, 2023, was 38 mL/min/1.73m², consistent with his CKD stage 3B classification.

Mr. Brown is currently on a multi-drug regimen to manage his conditions. For blood pressure control and renal protection, he is prescribed losartan 50 mg orally once daily and amlodipine 5 mg orally once daily. His type 2 diabetes is being managed with metformin 500 mg orally twice daily. Additionally, he is taking calcitriol 0.25 mcg orally once daily, likely to address vitamin D metabolism abnormalities associated with his chronic kidney disease.

Active monitoring orders are in place for both renal function and electrolytes, each scheduled at intervals of every three months, reflecting appropriate surveillance given his stage 3B CKD and concurrent medication use.

James Brown is a male born in 1958. He has no known drug allergies (documented as “No known allergy,” active and confirmed).

His active, confirmed problem list includes chronic kidney disease (CKD) stage 3B, described as stage 3b CKD with eGFR 38 and recorded with severe severity. He also has type 2 diabetes mellitus (active/confirmed) with diabetic nephropathy/diabetic chronic kidney disease (renal disorder due to diabetes mellitus; active/confirmed). In addition, he has hypertension (essential/primary; active/confirmed).

A laboratory observation shows an estimated glomerular filtration rate (eGFR, CKD-EPI 2021) of 38 mL/min/1.73 m², interpreted as low, with a referenced normal range of ≥90 mL/min/1.73 m².

Current active medication orders include:

• Losartan potassium 50 mg oral tablet: 50 mg by mouth once daily, prescribed for renal protection in the context of diabetic nephropathy and CKD stage 3b.
• Metformin hydrochloride 500 mg oral tablet: 500 mg by mouth twice daily, noted as a reduced dose for CKD; the record specifies it was reduced due to CKD stage 3b (eGFR 38) with instruction to monitor renal function regularly.
• Amlodipine 5 mg oral tablet: 5 mg by mouth once daily for blood pressure control.
• Calcitriol 0.25 mcg oral capsule: 0.25 mcg by mouth once daily for vitamin D deficiency, noted as secondary to CKD.

Active ordered laboratory monitoring includes:

• Renal function panel (serum/plasma) ordered for CKD stage 3B, with a note indicating regular monitoring is needed for CKD management and metformin dose adjustment.
• Electrolytes panel (serum/plasma) ordered for CKD stage 3B, with a note indicating regular electrolyte monitoring due to CKD and losartan because of risk of hyperkalemia.

No appointment or scheduling details are provided in the available records.